← All trials
NCT05103046
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2021
- Primary completion
- Dec 15, 2024
- Completion date
- Dec 15, 2025
- First posted
- Nov 2, 2021
- Last posted
- Nov 2, 2021
- Enrollment
- 68
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- 1200 Pharma, LLCLead sponsor
- Translational Research in OncologyCollaborator
- 1200 Pharma, LLCStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.